La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Apyx Medical Performance dei guadagni passati
Il passato criteri di controllo 0/6
Apyx Medical's earnings have been declining at an average annual rate of -7.4%, while the Medical Equipment industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 16.1% per year.
Informazioni chiave
-7.4%
Tasso di crescita degli utili
-6.9%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.9% |
| Tasso di crescita dei ricavi | 16.1% |
| Rendimento del capitale proprio | -190.8% |
| Margine netto | -57.9% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M
Aug 11Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin
Jul 18Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth
May 26Ripartizione dei ricavi e delle spese
Come Apyx Medical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 49 | -28 | 48 | 5 |
| 31 Mar 24 | 50 | -23 | 48 | 5 |
| 31 Dec 23 | 52 | -19 | 49 | 5 |
| 30 Sep 23 | 50 | -15 | 48 | 5 |
| 30 Jun 23 | 47 | -16 | 48 | 5 |
| 31 Mar 23 | 44 | -21 | 47 | 5 |
| 31 Dec 22 | 45 | -23 | 48 | 5 |
| 30 Sep 22 | 49 | -19 | 48 | 4 |
| 30 Jun 22 | 51 | -18 | 48 | 4 |
| 31 Mar 22 | 52 | -16 | 47 | 4 |
| 31 Dec 21 | 49 | -15 | 44 | 4 |
| 30 Sep 21 | 43 | -15 | 40 | 4 |
| 30 Jun 21 | 38 | -14 | 37 | 4 |
| 31 Mar 21 | 31 | -15 | 34 | 4 |
| 31 Dec 20 | 28 | -12 | 34 | 4 |
| 30 Sep 20 | 25 | -16 | 34 | 4 |
| 30 Jun 20 | 25 | -16 | 35 | 4 |
| 31 Mar 20 | 28 | -16 | 36 | 4 |
| 31 Dec 19 | 28 | -20 | 35 | 4 |
| 30 Sep 19 | 26 | -18 | 34 | 3 |
| 30 Jun 19 | 22 | -15 | 29 | 3 |
| 31 Mar 19 | 19 | -14 | 26 | 3 |
| 31 Dec 18 | 17 | -11 | 22 | 3 |
| 30 Sep 18 | 14 | -10 | 18 | 2 |
| 30 Jun 18 | 13 | -12 | 17 | 2 |
| 31 Mar 18 | 5 | -15 | 17 | 2 |
| 31 Dec 17 | 10 | -14 | 17 | 2 |
| 30 Sep 17 | -12 | -19 | 15 | 1 |
| 30 Jun 17 | -4 | -17 | 15 | 1 |
| 31 Mar 17 | 37 | -4 | 20 | 3 |
| 31 Dec 16 | 9 | -12 | 15 | 1 |
| 30 Sep 16 | 35 | -5 | 18 | 3 |
| 30 Jun 16 | 33 | -5 | 18 | 2 |
| 31 Mar 16 | 31 | -6 | 18 | 2 |
| 31 Dec 15 | 30 | 8 | 17 | 2 |
| 30 Sep 15 | 29 | 4 | 17 | 2 |
| 30 Jun 15 | 28 | 3 | 16 | 2 |
| 31 Mar 15 | 27 | 4 | 16 | 2 |
| 31 Dec 14 | 28 | -18 | 13 | 1 |
| 30 Sep 14 | 26 | -18 | 14 | 1 |
| 30 Jun 14 | 25 | -15 | 11 | 1 |
| 31 Mar 14 | 24 | -16 | 11 | 1 |
| 31 Dec 13 | 24 | -7 | 12 | 1 |
| 30 Sep 13 | 24 | -2 | 10 | 1 |
Guadagni di qualità: APYX is currently unprofitable.
Margine di profitto in crescita: APYX is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: APYX is unprofitable, and losses have increased over the past 5 years at a rate of 7.4% per year.
Accelerare la crescita: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).
Rendimento del capitale proprio
ROE elevato: APYX has a negative Return on Equity (-190.8%), as it is currently unprofitable.